MYND Life Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYNDF research report →
Price Chart
About the company
MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the United States, concentrating on therapeutic compounds that possess neuro-anti-inflammatory properties.
- CEO
- Wilfred A. Jefferies
- IPO
- 2021
- HQ
- Port Coquitlam, BC, CA
Get TickerSpark's AI analysis on MYNDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $657.84K
- P/E
- -2.18
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -0.66
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 35.68%
- ROIC
- 91.43%
Latest fiscal year · YoY change
- Revenue
- $92.99K+0.0%
- Gross Profit
- $-240,000-33.3%
- Op Income
- $-1,828,763
- Net Income
- $-1,517,860+57.5%
- EPS
- $-0.03+58.0%
- OCF Growth
- +89.1%
- FCF Growth
- +89.1%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.98
- RSI (14)
- 25
- Avg Volume
- 6.25K
No earnings-call transcripts are available for MYNDF yet.
- Free Float
- 100.0%
- Shares Outstanding
- 81.22M
- Float Shares
- 81.22M
Our MYNDF coverage
Recent articles, reports, and earnings notes.
No research on MYNDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYNDF report →MYND Life Sciences Announces Shares for Debt Transaction
newsfilecorp.com · Feb 11
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
newsfilecorp.com · Jan 17
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
newsfilecorp.com · Jan 10
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
newsfilecorp.com · Nov 22
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
newsfilecorp.com · Nov 12
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
newsfilecorp.com · Jan 30
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
newsfilecorp.com · Dec 5
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
newsfilecorp.com · Dec 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.